Andere Sprachen Janux Therapeutics, Inc.

Aktien

A3CR8F

US47103J1051

JANX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 12.06.2024			% 5 Tage	% 1. Jan.
42,75 ^USD	+1,69 %		-8,60 %	+298,42 %

06.06.	Janux Therapeutics Insider verkaufte Aktien im Wert von $45,043,975, laut einer aktuellen SEC Einreichung	MT
06.06.	Janux Therapeutics Insider verkaufte Aktien im Wert von $82,125,000, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing	06.06.
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing	06.06.
Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30.05.
Certain Stock Options of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30.05.
Certain Common Stock of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30.05.
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	07.05.
Sector Update: Health Care Stocks Slipping Late Afternoon	10.04.
Sector Update: Health Care	10.04.
Janux Therapeutics Said to be Considering Sale	10.04.
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports	10.04.
Janux Therapeutics Reportedly Weighs Possible Sale	10.04.
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases	08.03.
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08.03.
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08.03.
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	08.03.
Janux Therapeutics Prices $296.5 Million Offering of Common Stock, Pre-Funded Warrants	29.02.
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants	29.02.
Janux Therapeutics Announces Proposed Public Offering of Common Stock	27.02.
Sector Update: Health Care Stocks Ease Late Afternoon	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Janux Therapeutics, Inc.

Aktien

A3CR8F

US47103J1051

JANX

Andere Sprachen

Filter